<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39340739</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2629-3277</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Stem cell reviews and reports</Title><ISOAbbreviation>Stem Cell Rev Rep</ISOAbbreviation></Journal><ArticleTitle>Targeting Cytokines: Evaluating the Potential of Mesenchymal Stem Cell Derived Extracellular Vesicles in the Management of COVID-19.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12015-024-10794-4</ELocationID><Abstract><AbstractText>The Coronavirus Disease 2019 (COVID-19), caused by virus SARS-CoV-2, is characterized by massive inflammation and immune system imbalance. Despite the implementation of vaccination protocols, the accessibility of treatment remains uneven. Furthermore, the persistent threat of new variants underscores the urgent need for expanded research into therapeutic options for SARS-CoV-2. Mesenchymal stem cells (MSCs) are known for their immunomodulatory potential through the release of molecules into the extracellular space, either as soluble elements or carried by extracellular vesicles (EVs). The aim of this study was to evaluate the anti-inflammatory potential of EVs obtained from human adipose tissue (ASC-EVs) against SARS-CoV-2 infection. ASC-EVs were purified by size-exclusion chromatography, and co-culture assays confirmed that ASC-EVs were internalized by human lung cells and could colocalize with SARS-CoV-2 into early and late endosomes. To determine the functionality of ASC-EVs, lung cells were infected with SARS-CoV-2 in the presence of increasing concentrations of ASC-EVs, and the release of cytokines, chemokines and viruses were measured. While SARS-CoV-2 replication was significantly reduced only at the highest concentrations tested, multiplex analysis highlighted that lower concentrations of ASC-EV sufficed to prevent the production of immune modulators. Importantly, ASC-EVs did not contain detectable inflammatory cytokines, nor did they trigger inflammatory mediators, nor affect cellular viability. In conclusion, this work suggests that ASC-EVs have the potential to attenuate inflammation by decreasing the production of pro-inflammatory cytokines in lung cells following SARS-CoV-2 infection.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Iago Carvalho</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Santos Pereira Andrade</LastName><ForeName>Ana Claudia</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubuc</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laroche</LastName><ForeName>Audrée</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allaeys</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doré</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Axe Endocrinologie et Néphrologie, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculté de Pharmacie, Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallières</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Axe Neurosciences, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fradette</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEX, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Chirurgie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Regenerative Medicine, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flamand</LastName><ForeName>Louis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wink</LastName><ForeName>Marcia Rosangela</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boilard</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6319-6432</Identifier><AffiliationInfo><Affiliation>Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada. eric.boilard@crchudequebec.ulaval.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine de l'Université Laval, Québec, QC, Canada. eric.boilard@crchudequebec.ulaval.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stem Cell Rev Rep</MedlineTA><NlmUniqueID>101752767</NlmUniqueID><ISSNLinking>2629-3277</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Extracellular vesicles</Keyword><Keyword MajorTopicYN="N">Mesenchymal Stem Cell</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340739</ArticleId><ArticleId IdType="doi">10.1007/s12015-024-10794-4</ArticleId><ArticleId IdType="pii">10.1007/s12015-024-10794-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., … &amp; Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 382(8), 727–733. https://doi.org/10.1056/NEJMoa2001017</Citation></Reference><Reference><Citation>Gandhi, R. T., Lynch, J. B., &amp; del Rio, C. (2020). Mild or moderate Covid-19. New England Journal of Medicine,383(18), 1757–1766. https://doi.org/10.1056/nejmcp2009249</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmcp2009249</ArticleId><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin, D. A., Gulick, R. M., &amp; Martinez, F. J. (2020). Severe Covid-19. New England Journal of Medicine,383(25), 2451–2460. https://doi.org/10.1056/nejmcp2009575</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmcp2009575</ArticleId><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Danlos, F. X., Grajeda-Iglesias, C., Durand, S., Sauvat, A., Roumier, M., Cantin, D., … &amp; Kroemer, G. (2021). Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death and Disease, 12(3). https://doi.org/10.1038/s41419-021-03540-y</Citation></Reference><Reference><Citation>Broman, N., Rantasärkkä, K., Feuth, T., Valtonen, M., Waris, M., Hohenthal, U., … &amp; Oksi, J. (2021). IL-6 and other biomarkers as predictors of severity in COVID-19. Annals of Medicine, 53(1), 410–412. https://doi.org/10.1080/07853890.2020.1840621</Citation></Reference><Reference><Citation>Chen, C. H., Lin, S. W., Shen, C. F., Hsieh, K. S., &amp; Cheng, C. M. (2022). Biomarkers during COVID-19: Mechanisms of change and implications for patient outcomes. Diagnostics,12(2), 1–16. https://doi.org/10.3390/diagnostics12020509</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12020509</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., &amp; Lippi, G. (2020). Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM),58(7), 1021–1028. https://doi.org/10.1515/cclm-2020-0369</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0369</ArticleId><ArticleId IdType="pubmed">32286245</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu, T., Ning, W., Wu, D., Xu, J., Han, Q., Huang, M., … &amp; Zhou, X. (2020). Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity, 53(5), 1108–1122.e5. https://doi.org/10.1016/j.immuni.2020.10.008</Citation></Reference><Reference><Citation>Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., … &amp; Silvestre, R. (2021). Interleukin-6 Is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.613422</Citation></Reference><Reference><Citation>Li, L., Li, J., Gao, M., Fan, H., Wang, Y., Xu, X., … &amp; Yang, H. (2021). Interleukin-8 as a biomarker for disease prognosis of coronavirus disease-2019 patients. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.602395</Citation></Reference><Reference><Citation>Chen, Y., Wang, J., Liu, C., Su, L., Zhang, D., Fan, J., … &amp; Zhang, S. (2020). IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Molecular Medicine, 26(1). https://doi.org/10.1186/s10020-020-00230-x</Citation></Reference><Reference><Citation>Zaid, Y., Doré, É., Dubuc, I., Archambault, A. S., Flamand, O., Laviolette, M., … &amp; Flamand, L. (2021). Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. Journal of Allergy and Clinical Immunology, 148(2), 368–380.e3. https://doi.org/10.1016/j.jaci.2021.05.032</Citation></Reference><Reference><Citation>He, X., Yao, F., Chen, J., Wang, Y., Fang, X., Lin, X., … &amp; Wu, Q. (2021). The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Scientific Reports, 11(1), 1830. https://doi.org/10.1038/s41598-021-81300-w</Citation></Reference><Reference><Citation>Palareti, G., Legnani, C., Cosmi, B., Antonucci, E., Erba, N., Poli, D., … &amp; Tosetto, A. (2016). Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. International Journal of Laboratory Hematology, 38(1), 42–49. https://doi.org/10.1111/ijlh.12426</Citation></Reference><Reference><Citation>Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., … &amp; Becker, R. C. (2022). Current and novel biomarkers of thrombotic risk in COVID-19: A consensus statement from the international COVID-19 thrombosis biomarkers colloquium. Nature Reviews Cardiology, 0123456789. https://doi.org/10.1038/s41569-021-00665-7</Citation></Reference><Reference><Citation>Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. P. J., Kant, K. M., … &amp; Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research, 191(April), 145–147. https://doi.org/10.1016/j.thromres.2020.04.013</Citation></Reference><Reference><Citation>Levi, M., Thachil, J., Iba, T., &amp; Levy, J. H. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology,7(6), e438–e440. https://doi.org/10.1016/S2352-3026(20)30145-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30145-9</ArticleId><ArticleId IdType="pubmed">32407672</ArticleId><ArticleId IdType="pmc">7213964</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatar, M., Shoorekchali, J. M., Faraji, M. R., Seyyedkolaee, M. A., Pagán, J. A., &amp; Wilson, F. A. (2022). COVID-19 vaccine inequality: A global perspective. Journal of Global Health, 12. https://doi.org/10.7189/jogh.12.03072</Citation></Reference><Reference><Citation>del Rio, C., Collins, L. F., &amp; Malani, P. (2020). Long-term health consequences of COVID-19. JAMA,370, 2019–2020. https://doi.org/10.1001/jama.2020.19719</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau, O., Zins, M., Touvier, M., Wiernik, E., Lemogne, C., de Lamballerie, X., … &amp; Pastorino, B. (2022). Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Network Open, 5(11), e2240985. https://doi.org/10.1001/jamanetworkopen.2022.40985</Citation></Reference><Reference><Citation>Kappelmann, N., Dantzer, R., &amp; Khandaker, G. M. (2021). Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. Psychoneuroendocrinology,131(March), 105295. https://doi.org/10.1016/j.psyneuen.2021.105295</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2021.105295</ArticleId><ArticleId IdType="pubmed">34119855</ArticleId><ArticleId IdType="pmc">8172271</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., &amp; Boyton, R. J. (2023). The immunology of long COVID. Nature Reviews Immunology. https://doi.org/10.1038/s41577-023-00904-7 . Nature Research.</Citation></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M., &amp; Topol, E. J. (2023). Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology. https://doi.org/10.1038/s41579-022-00846-2 . Nature Research.</Citation></Reference><Reference><Citation>Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., &amp; Noël, D. (2010). Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. Stem Cell Research and Therapy,1(1), 1–7. https://doi.org/10.1186/scrt2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/scrt2</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., &amp; Caplan, A. I. (2019). Mesenchymal stem cell perspective: Cell biology to clinical progress. npj Regenerative Medicine. https://doi.org/10.1038/s41536-019-0083-6 . Nature Research.</Citation></Reference><Reference><Citation>Daher, S. R., Johnstone, B. H., Phinney, D. G., &amp; March, K. L. (2008). Adipose stromal/stem cells: Basic and translational advances: The IFATS collection. Stem Cells,26(10), 2664–2665. https://doi.org/10.1634/stemcells.2008-0927</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2008-0927</ArticleId><ArticleId IdType="pubmed">18818434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., … &amp; Hedrick, M. H. (2001). Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Engineering, 7(2), 211-228. Mary Ann Liebert, Inc.</Citation></Reference><Reference><Citation>Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., … &amp; Zhao, R. C. (2020). Transplantation of ACE2- Mesenchymal stem cells improves the outcome of patients with covid-19 pneumonia. Aging and Disease, 11(2), 216–228. https://doi.org/10.14336/AD.2020.0228</Citation></Reference><Reference><Citation>Grégoire, C., Layios, N., Lambermont, B., Lechanteur, C., Briquet, A., Bettonville, V., … &amp; Beguin, Y. (2022). Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: Preliminary results of a phase I/II clinical trial. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.932360</Citation></Reference><Reference><Citation>Liang, B., Chen, J., Li, T., Wu, H., Yang, W., Li, Y., … &amp; Hu, M. (2020). Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine, 99(31), e21429. https://doi.org/10.1097/MD.0000000000021429</Citation></Reference><Reference><Citation>de Dios, C., Vij, R., Kim, H., Park, H., &amp; Chang, D. (2023). Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: A randomized controlled trial. Frontiers in Medicine, 10. https://doi.org/10.3389/fmed.2023.1321303</Citation></Reference><Reference><Citation>Canbaz, H., İdiz, U. O., Dal, H. C., Kaçıroğlu, F., Taş, S., Çubukçu, H. C., … &amp; Akın, H. (2022). Effectiveness of mesenchymal stem cell therapy for COVID-19 patients in the intensive care unit: A case-control study. Turkish Journal of Hematology, 39(4), 222–229. https://doi.org/10.4274/tjh.galenos.2022.2022.0103</Citation></Reference><Reference><Citation>Fathi-Kazerooni, M., Fattah-Ghazi, S., Darzi, M., Makarem, J., Nasiri, R., Salahshour, F., … &amp; Kazemnejad, S. (2022). Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: Clinical trial phase I &amp; II. Stem Cell Research and Therapy, 13(1). https://doi.org/10.1186/s13287-022-02771-w</Citation></Reference><Reference><Citation>Rossello-Gelabert, M., Gonzalez-Pujana, A., Igartua, M., Santos-Vizcaino, E., &amp; Hernandez, R. M. (2022). Clinical progress in MSC-based therapies for the management of severe COVID-19. Cytokine and Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2022.07.002 . Elsevier Ltd.</Citation></Reference><Reference><Citation>Xu, X., Jiang, W., Chen, L., Xu, Z., Zhang, Q., Zhu, M., … &amp; Li, L. (2021). Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial. Clinical and Translational Medicine, 11(2). https://doi.org/10.1002/ctm2.297</Citation></Reference><Reference><Citation>Kaffash Farkhad, N., Sedaghat, A., Reihani, H., Adhami Moghadam, A., Bagheri Moghadam, A., Khadem Ghaebi, N., … &amp; Tavakol-Afshari, J. (2022). Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Research and Therapy, 13(1). https://doi.org/10.1186/s13287-022-02920-1</Citation></Reference><Reference><Citation>Aghayan, H. R., Salimian, F., Abedini, A., Fattah Ghazi, S., Yunesian, M., Alavi-Moghadam, S., … &amp; Sarrami-Forooshani, R. (2022). Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): Safety profile assessment. Stem Cell Research and Therapy, 13(1). https://doi.org/10.1186/s13287-022-02953-6</Citation></Reference><Reference><Citation>Li, T. T., Zhang, B., Fang, H., Shi, M., Yao, W. Q., Li, Y., … &amp; Wang, F. S. (2023). Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial. eBioMedicine, 92. https://doi.org/10.1016/j.ebiom.2023.104600</Citation></Reference><Reference><Citation>Soetjahjo, B., Malueka, R. G., Nurudhin, A., Purwoko, Sumardi, Wisaksana, R., … &amp; Faried, A. (2023). Effectiveness and safety of normoxic allogenic umbilical cord mesenchymal stem cells administered as adjunctive treatment in patients with severe COVID-19. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-39268-2</Citation></Reference><Reference><Citation>Zarrabi, M., Shahrbaf, M. A., Nouri, M., Shekari, F., Hosseini, S. E., Hashemian, S. M. R., … &amp; Baharvand, H. (2023). Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: A randomized controlled trial. Stem Cell Research and Therapy, 14(1). https://doi.org/10.1186/s13287-023-03402-8</Citation></Reference><Reference><Citation>Rebelatto, C. L. K., Senegaglia, A. C., Franck, C. L., Daga, D. R., Shigunov, P., Stimamiglio, M. A., … &amp; Correa, A. (2022). Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: A randomized clinical trial. Stem Cell Research and Therapy, 13(1). https://doi.org/10.1186/s13287-022-02796-1</Citation></Reference><Reference><Citation>Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., &amp; Caplan, A. I. (2019). Mesenchymal stem cell perspective: Cell biology to clinical progress. npj Regenerative Medicine,4(1), 22. https://doi.org/10.1038/s41536-019-0083-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41536-019-0083-6</ArticleId><ArticleId IdType="pubmed">31815001</ArticleId><ArticleId IdType="pmc">6889290</ArticleId></ArticleIdList></Reference><Reference><Citation>Öztürk, S., Elçin, A. E., Koca, A., &amp; Elçin, Y. M. (2020). Therapeutic applications of stem cells and extracellular vesicles in emergency care: Futuristic perspectives. Stem Cell Reviews and Reports. https://doi.org/10.1007/s12015-020-10029-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10029-2</ArticleId><ArticleId IdType="pmc">7444453</ArticleId></ArticleIdList></Reference><Reference><Citation>El Andaloussi, S., Mäger, I., Breakefield, X. O., &amp; Wood, M. J. A. (2013). Extracellular vesicles: Biology and emerging therapeutic opportunities. Nature Reviews Drug Discovery,12(5), 347–357. https://doi.org/10.1038/nrd3978</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3978</ArticleId><ArticleId IdType="pubmed">23584393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, G., Huang, R., Qiu, G., Ge, M., Wang, J., Shu, Q., &amp; Xu, J. (2018). Mesenchymal stromal cell-derived extracellular vesicles: Regenerative and immunomodulatory effects and potential applications in sepsis. Cell and Tissue Research, 374(1). https://doi.org/10.1007/s00441-018-2871-5</Citation></Reference><Reference><Citation>Wiklander, O. P. B., Brennan, M., Lötvall, J., Breakefield, X. O., &amp; Andaloussi, S. E. L. (2019). Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine, 11(492). https://doi.org/10.1126/scitranslmed.aav8521</Citation></Reference><Reference><Citation>Abraham, A., &amp; Krasnodembskaya, A. (2020). Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Translational Medicine,9(1), 28–38. https://doi.org/10.1002/sctm.19-0205</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.19-0205</ArticleId><ArticleId IdType="pubmed">31647191</ArticleId></ArticleIdList></Reference><Reference><Citation>Meldolesi, J. (2021). News about the extracellular vesicles from mesenchymal stem cells: Functions, therapy and protection from COVID-19. Journal of Experimental Pathology,2(1), 47–52. https://doi.org/10.33696/pathology.2.015</Citation><ArticleIdList><ArticleId IdType="doi">10.33696/pathology.2.015</ArticleId><ArticleId IdType="pubmed">33786534</ArticleId></ArticleIdList></Reference><Reference><Citation>Norouzi-Barough, L., Asgari Khosroshahi, A., Gorji, A., Zafari, F., Shahverdi Shahraki, M., &amp; Shirian, S. (2022). COVID-19-Induced stroke and the potential of using mesenchymal stem cells-derived extracellular vesicles in the regulation of neuroinflammation. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-021-01169-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-021-01169-1</ArticleId><ArticleId IdType="pubmed">35025001</ArticleId><ArticleId IdType="pmc">8755896</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu, M., Wang, H., Bian, L., Huang, J., Wu, D., Zhang, R., … &amp; Xia, J. (2022). Nebulization therapy with umbilical cord mesenchymal stem cell-derived exosomes for COVID-19 pneumonia. Stem Cell Reviews and Reports, 18(6), 2152–2163. https://doi.org/10.1007/s12015-022-10398-w</Citation></Reference><Reference><Citation>Lightner, A. L., Sengupta, V., Qian, S., Ransom, J. T., Suzuki, S., Park, D. J., … &amp; Awili, M. (2023). Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: A randomized, placebo-controlled dosing clinical trial. Chest, 164(6), 1444–1453. https://doi.org/10.1016/j.chest.2023.06.024</Citation></Reference><Reference><Citation>Chutipongtanate, S., Kongsomros, S., Pongsakul, N., Panachan, J., Khowawisetsut, L., Pattanapanyasat, K., … &amp; Thitithanyanont, A. (2022). Anti-SARS-CoV-2 effect of extracellular vesicles released from mesenchymal stem cells. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12201 . John Wiley and Sons Inc.</Citation></Reference><Reference><Citation>Vermette, M., Trottier, V., Ménard, V., Saint-Pierre, L., Roy, A., &amp; Fradette, J. (2007). Production of a new tissue-engineered adipose substitute from human adipose-derived stromal cells. Biomaterials,28(18), 2850–2860. https://doi.org/10.1016/j.biomaterials.2007.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2007.02.030</ArticleId><ArticleId IdType="pubmed">17374391</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbraith, T., Clafshenkel, W. P., Kawecki, F., Blanckaert, C., Labbé, B., Fortin, M., … &amp; Fradette, J. (2017). A cell-based self-assembly approach for the production of human osseous tissues from adipose-derived stromal/stem cells. Advanced Healthcare Materials, 6(4). https://doi.org/10.1002/adhm.201600889</Citation></Reference><Reference><Citation>Witwer, K. W., Van Balkom, B. W. M., Bruno, S., Choo, A., Dominici, M., Gimona, M., … &amp; Lim, S. K. (2019). Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 8(1). https://doi.org/10.1080/20013078.2019.1609206</Citation></Reference><Reference><Citation>Ramos, T. L., Sánchez-Abarca, L. I., Muntión, S., Preciado, S., Puig, N., López-Ruano, G., … &amp; Del Cañizo, C. (2016). MSC surface markers (CD44, CD73, and CD90) can identify human MSC-derived extracellular vesicles by conventional flow cytometry. Cell Communication and Signaling, 14(1). https://doi.org/10.1186/s12964-015-0124-8</Citation></Reference><Reference><Citation>Welsh, J. A., Goberdhan, D. C. I., O’Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., … &amp; Zubair, H. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 13(2). https://doi.org/10.1002/jev2.12404</Citation></Reference><Reference><Citation>Böing, A. N., van der Pol, E., Grootemaat, A. E., Coumans, F. A. W., Sturk, A., &amp; Nieuwland, R. (2014). Single-step isolation of extracellular vesicles by size-exclusion chromatography. Journal of Extracellular Vesicles, 3(1). https://doi.org/10.3402/jev.v3.23430</Citation></Reference><Reference><Citation>Monguió-Tortajada, M., Gálvez-Montón, C., Bayes-Genis, A., Roura, S., &amp; Borràs, F. E. (2019). Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-019-03071-y . Birkhauser Verlag AG.</Citation></Reference><Reference><Citation>Zhou, C., Cox-Vázquez, S. J., Chia, G. W. N., Vázquez, R. J., Lai, H. Y., Chan, S. J. W., … &amp; Bazan, G. C. (2023). Water-soluble extracellular vesicle probes based on conjugated oligoelectrolytes. Retrieved from: https://www.science.org</Citation></Reference><Reference><Citation>Hu, X., Pan, J., Li, Y., Jiang, Y., Zheng, H., Shi, R., … &amp; Wang, Y. (2022). Extracellular vesicles from adipose-derived stem cells promote microglia M2 polarization and neurological recovery in a mouse model of transient middle cerebral artery occlusion. Stem Cell Research and Therapy, 13(1). https://doi.org/10.1186/s13287-021-02668-0</Citation></Reference><Reference><Citation>Ma, S., Song, L., Bai, Y., Wang, S., Wang, J., Zhang, H., … &amp; Qin, G. (2023). Improved intracellular delivery of exosomes by surface modification with fluorinated peptide dendrimers for promoting angiogenesis and migration of HUVECs. RSC Advances, 13(17), 11269–11277. https://doi.org/10.1039/d3ra00300k</Citation></Reference><Reference><Citation>Wu, D., Liu, X., &amp; Jin, Z. (2023). Adipose-derived mesenchymal stem cells-sourced exosomal microRNA-7846-3p suppresses proliferation and pro-angiogenic role of keloid fibroblasts by suppressing neuropilin 2. Journal of Cosmetic Dermatology,22(8), 2333–2342. https://doi.org/10.1111/jocd.15721</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocd.15721</ArticleId><ArticleId IdType="pubmed">37025072</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y., Zhang, J., Shi, J., Liu, K., Wang, X., Jia, Y., … &amp; Hu, D. (2021). Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192–5p/IL-17RA/Smad axis. Stem Cell Research and Therapy, 12(1). https://doi.org/10.1186/s13287-021-02290-0</Citation></Reference><Reference><Citation>Feng, C. Y., Bai, S. Y., Li, M. L., Zhao, J. Y., Sun, J. M., Bao, H. J., … &amp; Su, X. M. (2022). Adipose-derived mesenchymal stem cell-derived exosomal miR-301a-3p regulates airway smooth muscle cells during asthma by targeting STAT3. Journal of Asthma and Allergy, 15, 99–110. https://doi.org/10.2147/JAA.S335680</Citation></Reference><Reference><Citation>Wang, X., Liu, D., Zhang, X. H., Yang, L. M., Xia, Z., &amp; Zhang, Q. (2022). Exosomes from adipose-derived mesenchymal stem cells alleviate sepsis-induced lung injury in mice by inhibiting the secretion of IL-27 in macrophages. Cell Death Discovery, 8(1). https://doi.org/10.1038/s41420-021-00785-6</Citation></Reference><Reference><Citation>van der Pol, E., Coumans, F. A. W., Grootemaat, A. E., Gardiner, C., Sargent, I. L., Harrison, P., … &amp; Nieuwland, R. (2014). Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. Journal of Thrombosis and Haemostasis, 12(7), 1182–1192. https://doi.org/10.1111/jth.12602</Citation></Reference><Reference><Citation>Vestad, B., Llorente, A., Neurauter, A., Phuyal, S., Kierulf, B., Kierulf, P., … &amp; Øvstebø, R. (2017). Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. Journal of Extracellular Vesicles, 6(1). https://doi.org/10.1080/20013078.2017.1344087</Citation></Reference><Reference><Citation>TechBrief_NTA_LOD_Sample_Dependent_v0. (n.d.).</Citation></Reference><Reference><Citation>Hunter, C. A., &amp; Jones, S. A. (2015). IL-6 as a keystone cytokine in health and disease. Nature Immunology,16(5), 448–457. https://doi.org/10.1038/ni.3153</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3153</ArticleId><ArticleId IdType="pubmed">25898198</ArticleId></ArticleIdList></Reference><Reference><Citation>Basiri, A., Pazhouhnia, Z., Beheshtizadeh, N., Hoseinpour, M., Saghazadeh, A., &amp; Rezaei, N. (2020). Regenerative medicine in COVID-19 treatment: Real opportunities and range of promises. Stem Cell Reviews and Reports. https://doi.org/10.1007/s12015-020-09994-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-09994-5</ArticleId><ArticleId IdType="pmc">7305935</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S., Peng, D., Qiu, H., Yang, K., Fu, Z., &amp; Zou, L. (2020). Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Research and Therapy,11(1), 8–11. https://doi.org/10.1186/s13287-020-01678-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01678-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkoc, T. (2020). COVID-19 and mesenchymal stem cell treatment; Mystery or not. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/5584_2020_557</Citation></Reference><Reference><Citation>Shi, L., Wang, L., Xu, R., Zhang, C., Xie, Y., Liu, K., … &amp; Wang, F. S. (2021). Mesenchymal stem cell therapy for severe COVID-19. Signal Transduction and Targeted Therapy, 6(1), 1–5. https://doi.org/10.1038/s41392-021-00754-6</Citation></Reference><Reference><Citation>Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W. C., Uhl, S., Hoagland, D., Møller, R., … &amp; tenOever, B. R. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181(5), 1036–1045.e9. https://doi.org/10.1016/j.cell.2020.04.026</Citation></Reference><Reference><Citation>Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., &amp; Perlman, S. (2016). Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-Infected mice. Cell Host and Microbe,19(2), 181–193. https://doi.org/10.1016/j.chom.2016.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.01.007</ArticleId><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., … &amp; Kernéis, S. (n.d.). Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. https://doi.org/10.1101/2020.04.19.20068015</Citation></Reference><Reference><Citation>Soni, N., Tripathi, A., Mukherjee, S., Gupta, S., Mohanty, S., Basu, A., &amp; Banerjee, A. (2022). Bone marrow-derived extracellular vesicles modulate the abundance of infiltrating immune cells in the brain and exert an antiviral effect against the Japanese encephalitis virus. FASEB BioAdvances,4(12), 798–815. https://doi.org/10.1096/fba.2022-00071</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fba.2022-00071</ArticleId><ArticleId IdType="pubmed">36479206</ArticleId><ArticleId IdType="pmc">9721092</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian, X., Xu, C., Fang, S., Zhao, P., Wang, Y., Liu, H., … &amp; Qi, Z. (2016). Exosomal MicroRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection. Stem Cells Translational Medicine, 5(9), 1190–1203. https://doi.org/10.5966/sctm.2015-0348</Citation></Reference><Reference><Citation>Rocha, J. L. M., de Oliveira, W. C. F., Noronha, N. C., dos Santos, N. C. D., Covas, D. T., Picanço-Castro, V., … &amp; Malmegrim, K. C. R. (2021). Mesenchymal stromal cells in viral infections: Implications for COVID-19. Stem Cell Reviews and Reports. https://doi.org/10.1007/s12015-020-10032-7 . Springer.</Citation></Reference><Reference><Citation>Wu, X., Dao Thi, V. L., Huang, Y., Billerbeck, E., Saha, D., Hoffmann, H. H., … &amp; Rice, C. M. (2018). Intrinsic immunity shapes viral resistance of stem cells. Cell, 172(3), 423–438.e25. https://doi.org/10.1016/j.cell.2017.11.018</Citation></Reference><Reference><Citation>Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., &amp; Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA - Journal of the American Medical Association,324(8), 782–793. https://doi.org/10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuchowski, M. F., Winkler, M. S., Skirecki, T., Cajander, S., Shankar-Hari, M., Lachmann, G., … &amp; Rubio, I. (2021). The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. The Lancet Respiratory Medicine, 9(6), 622–642. https://doi.org/10.1016/S2213-2600(21)00218-6</Citation></Reference><Reference><Citation>Trump, S., Lukassen, S., Anker, M. S., Chua, R. L., Liebig, J., Thürmann, L., … &amp; Lehmann, I. (2020). Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nature Biotechnology. https://doi.org/10.1038/s41587-020-00796-1</Citation></Reference><Reference><Citation>Joshi, B. S., de Beer, M. A., Giepmans, B. N. G., &amp; Zuhorn, I. S. (2020). Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano,14(4), 4444–4455. https://doi.org/10.1021/acsnano.9b10033</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.9b10033</ArticleId><ArticleId IdType="pubmed">32282185</ArticleId><ArticleId IdType="pmc">7199215</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulcahy, L. A., Pink, R. C., &amp; Carter, D. R. F. (2014). Routes and mechanisms of extracellular vesicle uptake. Journal of Extracellular Vesicles. https://doi.org/10.3402/jev.v3.24641 . Co-Action Publishing.</Citation></Reference><Reference><Citation>Pham, T. T., Chen, H., Nguyen, P. H. D., Jayasinghe, M. K., Le, A. H., &amp; Le, M. T. (2023). Endosomal escape of nucleic acids from extracellular vesicles mediates functional therapeutic delivery. Pharmacological Research, 188. https://doi.org/10.1016/j.phrs.2023.106665</Citation></Reference><Reference><Citation>O’Brien, K., Ughetto, S., Mahjoum, S., Nair, A. V., &amp; Breakefield, X. O. (2022). Uptake, functionality, and re-release of extracellular vesicle-encapsulated cargo. Cell Reports, 39(2). https://doi.org/10.1016/j.celrep.2022.110651</Citation></Reference><Reference><Citation>Casella, G., Colombo, F., Finardi, A., Descamps, H., Ill-Raga, G., Spinelli, A., … &amp; Furlan, R. (2018). Extracellular vesicles containing IL-4 modulate neuroinflammation in a mouse model of multiple sclerosis. Molecular Therapy, 26(9), 2107–2118. https://doi.org/10.1016/j.ymthe.2018.06.024</Citation></Reference><Reference><Citation>Riazifar, M., Mohammadi, M. R., Pone, E. J., Yeri, A., Lasser, C., Segaliny, A. I., … &amp; Zhao, W. (2019). Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano, 13(6), 6670–6688. https://doi.org/10.1021/acsnano.9b01004</Citation></Reference><Reference><Citation>Shang, R., Lee, S., Senavirathne, G., &amp; Lai, E. C. (2023). microRNAs in action: Biogenesis, function and regulation. Nature Reviews Genetics. https://doi.org/10.1038/s41576-023-00611-y . Nature Research.</Citation></Reference><Reference><Citation>Schultz, I. C., Bertoni, A. P. S., &amp; Wink, M. R. (2021). Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: An in silico analysis. Stem Cell Reviews and Reports,17(2), 341–356. https://doi.org/10.1007/s12015-021-10122-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-021-10122-0</ArticleId><ArticleId IdType="pubmed">33511519</ArticleId><ArticleId IdType="pmc">7842178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu, R. J., Yu, W. C., Peng, G. R., Ye, C. H., Hu, S. Y., Chong, P. C. T., … &amp; Yu, S. H. (2022). The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.832394 . Frontiers Media S.A.</Citation></Reference><Reference><Citation>Cesta, M. C., Zippoli, M., Marsiglia, C., Gavioli, E. M., Mantelli, F., Allegretti, M., &amp; Balk, R. A. (2022). The role of Interleukin-8 in lung inflammation and injury: Implications for the management of COVID-19 and hyperinflammatory acute respiratory distress syndrome. Frontiers in Pharmacology https://doi.org/10.3389/fphar.2021.808797 . Frontiers Media S.A.</Citation></Reference><Reference><Citation>Boilard, E. (2018). Extracellular vesicles and their content in bioactive lipid mediators: More than a sack of microRNA. Journal of Lipid Research. https://doi.org/10.1194/jlr.R084640 . American Society for Biochemistry and Molecular Biology Inc.</Citation></Reference><Reference><Citation>Zou, Q., Liu, C., Hu, N., Wang, W., &amp; Wang, H. (2022). miR-126 ameliorates multiple organ dysfunction in septic rats by regulating the differentiation of Th17/Treg. Molecular Biology Reports,49(4), 2985–2998. https://doi.org/10.1007/s11033-022-07121-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07121-w</ArticleId><ArticleId IdType="pubmed">35122598</ArticleId><ArticleId IdType="pmc">8817156</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh, Y. S., Bae, G. D., Park, E. Y., &amp; Jun, H. S. (2019). MicroRNA-181c inhibits interleukin-6-mediated beta cell apoptosis by targeting TNF-α expression. Molecules, 24(7). https://doi.org/10.3390/molecules24071410</Citation></Reference><Reference><Citation>Chakraborty, C., Sharma, A. R., Sharma, G., &amp; Lee, S. S. (2020). The interplay among miRNAs, major cytokines, and cancer-related inflammation. Molecular Therapy Nucleic Acids. https://doi.org/10.1016/j.omtn.2020.04.002 . Cell Press.</Citation></Reference><Reference><Citation>Salvi, V., Gianello, V., Tiberio, L., Sozzani, S., &amp; Bosisio, D. (2019). Cytokine targeting by miRNAs in autoimmune diseases. Frontiers in Immunology, 10(JAN). https://doi.org/10.3389/fimmu.2019.00015</Citation></Reference><Reference><Citation>Yang, Z., Guo, Z., Dong, J., Sheng, S., Wang, Y., Yu, L., … &amp; Tang, L. (2018). miR-374a regulates inflammatory response in diabetic nephropathy by targeting MCP-1 expression. Frontiers in Pharmacology, 9(AUG). https://doi.org/10.3389/fphar.2018.00900</Citation></Reference><Reference><Citation>Doumatey, A. P., He, W. J., Gaye, A., Lei, L., Zhou, J., Gibbons, G. H., … &amp; Rotimi, C. N. (2018). Circulating MiR-374a-5p is a potential modulator of the inflammatory process in obesity. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-26065-5</Citation></Reference><Reference><Citation>Ji, X., Yang, L., Zhang, Z., Zhang, K., Chang, N., Zhou, X., … &amp; Li, L. (2020). Sphingosine 1-phosphate/microRNA-1249–5p/MCP-1 axis is involved in macrophage-associated inflammation in fatty liver injury in mice. European Journal of Immunology, 50(11), 1746–1756. https://doi.org/10.1002/eji.201948351</Citation></Reference><Reference><Citation>Perez-Sanchez, C., Betancourt, A. B., Lyons, P. A., Zhang, Z., Suo, C., Lee, J. C., … &amp; Smith, K. G. C. (2022). miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease. Journal of Experimental Medicine, 219(5). https://doi.org/10.1084/jem.20211366</Citation></Reference><Reference><Citation>Safoine, M., Côté, A., Leloup, R., Hayward, C. J., Plourde Campagna, M. A., Ruel, J., &amp; Fradette, J. (2022). Engineering naturally-derived human connective tissues for clinical applications using a serum-free production system. Biomedical Materials (Bristol), 17(5). https://doi.org/10.1088/1748-605X/ac84b9</Citation></Reference><Reference><Citation>Bourin, P., Bunnell, B. A., Casteilla, L., Dominici, M., Katz, A. J., March, K. L., … &amp; Gimble, J. M. (2013). Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy, 15(6), 641–648. https://doi.org/10.1016/j.jcyt.2013.02.006</Citation></Reference><Reference><Citation>Ramakrishnan, M. A. (2016). Determination of 50% endpoint titer using a simple formula. World Journal of Virology,5(2), 85. https://doi.org/10.5501/wjv.v5.i2.85</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v5.i2.85</ArticleId><ArticleId IdType="pubmed">27175354</ArticleId><ArticleId IdType="pmc">4861875</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>